CreoSG, a 'Medifood' Inducing Muscle Formation, Enters Global Market

On the 14th, CreoSG announced its entry into the global market for medifood (health functional food) that induces muscle formation. CreoSG expects its experience in the bio business, including vaccine development for various unresolved infectious diseases such as AIDS and research on immune oncology drugs, to be beneficial.

Hepatol, a natural products specialist company, judged that it would create synergy with the platform delivery technology owned by CreoSG, and last year signed a memorandum of understanding (MOU) for the "Development and business progress of anti-aging and muscle growth health functional food products using CAF," followed by a formal supply contract.

So far, the two companies have made various efforts to enter overseas markets with muscle-building beverages and powder products (Musclo) using CAF as the main ingredient. They will begin full-scale distribution and sales in markets including the domestic market, Southeast Asia, China, and Japan.

According to the company, C.A.F. (Cell Activation Factor), which was certified as a New Dietary Ingredient (NDI) by the U.S. Food and Drug Administration (FDA) for the first time in Korea, is a powerful antioxidant substance that increases cellular absorption of Seapolynol®, a marine polyphenol extracted from brown seaweed, and activates metabolism in the body.

It is a new bio-substance expected to make a significant contribution to anti-aging and health maintenance by showing excellent effects in reducing body fat and promoting healthy muscle formation through improving chronic inflammation, cell protection, and blood circulation.

Unlike directly consuming protein for muscle formation, it promotes the muscle synthesis metabolic process to generate muscle, so it does not have various side effects caused by excessive protein intake. It also overcomes insulin resistance and participates in the body's fat metabolism process, reducing body fat. This effect improves fatty liver, hyperlipidemia, obesity, diabetes, and also increases bone density, making it expected to replace the rapidly growing multi-trillion-won protein supplement market.

CreoSG plans to start distribution and sales in the Asian region through supply contracts for muscle-building beverages and powder products with Human Cell Medical in Southeast Asia, Shandong SC Technology Innovation Co., Ltd. in China, and Elumild in Japan. Starting with sales in the 10 billion KRW range this year, the company aims for 80 billion KRW in 2026, 120 billion KRW in 2027, and steady annual sales exceeding 200 billion KRW from 2028 onward, expanding sales and distribution in various forms.

A CreoSG official said, "We have officially launched products containing C.A.F., a powerful antioxidant substance with confirmed excellent effects, into the market," adding, "We are also considering expanding synergy research into anti-inflammatory and anti-cancer fields through our own platform in the future."